Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 15 of 15 for “"Antalarmin"”.
-
The importance of specific amino acid residues in transmembrane domains 3 and 5 of a corticotropin releasing-factor receptor for functional activity of a CRF-R1 selective small molecule antagonist
… the highly selective small molecule antagonist antalarmin. In order to further prove the importance of these sites, we have mutated the two corresponding amino acids in CRFR2β to those of CRFR1: V215H in TMD 3 and V292M in TMD 5. In addition, we mutated a third amino acid residue, M293I, in …
-
The protective actions of the cardiac CRF system in rainbow trout (Oncorhynchus mykiss) in response to hypoxia and reoxygenation
… of pre-treatment with 1.0 nM trout CRF or 10 nM antalarmin, a CRF type 1 receptor antagonist. All CRF system components are expressed in the heart where the dominant receptor type is CRF-2b and the dominant ligand is CRFa1. Antalarmin exerted significant negative inotropic and lusitropic effects …
-
Ο ρόλος του CRH στην in vitro ανάπτυξη αρχέγονων ωοθυλακίων και η δράση αυτού στην εμφύτευση
… the effect of hormone CRH and the inhibitor, antalarmin, in the in vitro maturation of preantral mouse follicles in early embryonic development but also in steroidogenesis, in producing glycoprotein hormones and a peptide hormone. We additionally performed Real-Time PCR to study the expression …
-
Synthesis and Biological Evaluation of Substituted Thiazolo(4,5-d)Pyrimidines and Substituted Pyrimidines as Corticotropin Releasing Factor (CRF) Receptor Antagonists
… determine their IC50 values. Comparison with Antalarmin, a potent CRF1 antagonist, were also carried out in competition binding study. None of the 22 substituted thiazolo[4,5-d]pyrimdines showed 50% or more inhibition at 1000 nM, and thus were not considered for the second evaluation protocol. …
-
The Effects of CRF1 Antagonism on Spatial Navigation and Long-Term Potentiation in the TgF344-AD Model of Alzheimer’s Disease
… stress. Administration of the CRF1 antagonist, Antalarmin, reduces AD pathogenesis and anxiety-like behavior in models of Alzheimer’s disease. Thus, the current project used the TgF344-AD model to elucidate the mechanistic functions of CRF1 on the progression of AD neuropathology. Through …
-
Μελέτη της δομής και λειτουργίας του τύπου 1 υποδοχέα του εκλυτικού παράγοντα της κορτικοτροπίνης
… have been shown to bind small molecules, such as antalarmin, a non-peptide antagonist of the type 1 receptor for CRF (CRF1). This leads to the hypothesis that similar to family A, rhodopsin-like, GPCRs, the TMs of subfamily B GPCRs form a water-accessible crevice, the binding-site crevice, which …
-
The involvement of the neuropeptides orexins (hypocretins) in fear and anxiety in rats exposed to a single episode of footshocks
… releasing factor receptor antagonist antalarmin were found to attenuate the anxiety expressed to the shock chamber and eliminate the correlation between ppOX mRNA levels and anxiety. Fourth, systemic injections of the nonselective orexin receptor antagonist TCS-1102 was found to …
-
HIV-1 Tat and Opioids: Implications for Stress-related Psychopathology
… (CRF-R) and/or GR via systemic administration of antalarmin and RU-486 attenuated psychomotor and anxiety-like behavior. Moreover, gonadal steroids like estradiol and progesterone ameliorated Tat-mediated neurotoxicity in cell cultures. Chapter 3 demonstrated the neuroprotective capacity of …
-
Επίδραση του συνθετικού εκλυτικού παράγοντα της κορτικοτροπίνης στο ανοσολογικό σύστημα
… εξέλιξη του shock. Βρήκαμε ότι η χορήγηση της antalarmin, ενός ειδικού συνθετικού αναστολέα των υποδοχέων CRHR1 της CRH, πριν από την χορήγηση της ενδοτοξίνης, παρέτεινε με στατιστικά σημαντικό τρόπο την επιβίωση των πειραματοζώων. Επιπλέον, η αναστολή των υποδοχέων CRHR1 ελάττωσε τα επίπεδα …
-
Διαλεύκανση της δομής της τρίτης διαμεμβρανικής περιοχής του τύπου 1 υποδοχέα του CRF, καθώς και των αλληλεπιδράσεών του με τον CRF και των αναλόγων του
… of the hydrophobic nonpeptide antagonist, antalarmin to receptor. Similarly, F2033.40A mutation abolished antalarmin binding to CRF1R. In marked contrast, the hydrophobic substitutions F2033.40W and F2033.40I did not decrease the binding and antagonistic properties of antalarmin. These …
-
Estimation of Ethanol/Water Solubility Profiles
… parabolic model.A solubility case study using Antalarmin, a novel stress inhibitor was performed.This study illustrates the use of cosolvents as solubility enhancers as well as pH,surfactants, complexants and lipid based systems.
-
The role of corticotropin releasing factor in the pathophysiology of schizophrenia
… blocked CRF1 in female MAM-16 mice, using antalarmin, which is a CRF1 specific antagonist. Our aim was to test whether CRF1 inactivation could induce PFC-dysfunction. We observed a disruption of LTP in the PFC of female MAM-exposed mice, in contrast to the facilitation we recorded in …
-
An intrinsic CRF signaling pathway in the optic tectum
… be displaced by the CRF R1 selective antagonists antalarmin or NBI 27914. CRF enhanced cAMP content in tectal slices in vitro, but the differences were not statistically significant. In order to figure out whether the control of CRF neurons is controlled by chemically defined pathways innervating …
-
Συμβολή του νευροπεπτιδίου εκλυτική ορμόνη της κορτικοτροπίνης (CRH) και των γλυκοκορτικοειδών στην τραυματική επούλωση
… The pharmacological blockade of CRF1 using antalarmin in cultured human fibroblasts led to similar changes on the rate of proliferation and migration and secretion of IL‐6, with those observed in Crh ‐/‐ fibroblasts. These results reinforce the importance of CRH in the biology of skin …
-
Study of the expression, the regulation and the biological role of the corticotropin releasing hormone (CRH) in endometriosis
… study results suggest that the potential use of antalarmin could be further considered in accessing the immune disequilibrium noticed in eutopic and ectopic endometrium of women with endometriosis.